ClinicalTrials.gg
RecruitingNCT07938086Updated Nov 16, 2026

Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk Test

An interventional study of EMILY.AI automatic oxygen titration and Fixed-flow oxygen in Chronic Obstructive Pulmonary Disease (COPD), Interstitial Lung Diseases and Pulmonary Hypertension, sponsored by Aether Tech S.L.. Recruiting at 1 site in Spain. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Aether Tech S.L. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Apr 2026, registered Oct 2026).
  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
40 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain — 42 open to participants now, 45 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Spain.

Planned enrollment
222nd of 238
24 · median 336
Started
2026
with 6 others
No phase
68 of 309
13 open now
Primary completion
2026-12
later than 22 of 44 live
Registered
308th of 309
by date

Among the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, this one is the 222nd largest by planned enrollment of the 238 interventional ones that give a count, is one of 7 that started in 2026, is one of 68 with no phase, reaches primary completion later than 22 of the 44 other live ones, and was the 308th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

42 of the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, or all of them as a file.
02

Study summary

This study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient, second by second, according to oxygen saturation (SpO2), heart rate and respiratory rate measured by a pulse oximeter.

Adults with chronic respiratory disease who need oxygen during exertion perform two six-minute walk tests on the same day, 30 minutes apart: one with oxygen adjusted automatically by EMILY.AI and one with a fixed oxygen flow delivered through the same device. The order is randomized and participants do not know which test uses automatic titration.

The study compares the time spent within the target saturation range, desaturation, oxygen use, walking distance, breathlessness and participant preference between the two tests. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.

Read the detailed description

Background Patients with chronic respiratory disease often desaturate during exertion, and fixed-flow oxygen cannot follow the rapid changes in oxygen demand during walking and recovery. EMILY.AI combines a medical-grade oxygen valve with an edge-computing fuzzy-logic algorithm that sets the oxygen flow every second, with continuous logging of physiological signals and delivered flow.

Design Pilot, pragmatic, single-blind, randomized crossover study at Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain). Each participant performs two supervised six-minute walk tests (6MWT) according to the American Thoracic Society guideline, separated by 30 minutes of rest: one with automatic titration by EMILY.AI and one with a fixed flow set by the physician, delivered through the same device so that the participant cannot tell them apart. The order of the two tests is randomized. Each test includes 6 minutes of walking and 2 minutes of standardized recovery.

Safety The medical team knows the device configuration and supervises the valve throughout each test.

Measurements SpO2, heart rate and respiratory rate are recorded with medical-grade pulse oximeters (Nonin, Masimo or Nihon Kohden models), together with distance walked, Borg dyspnoea score, oxygen delivered and participant-reported comfort, breathlessness and preference.

The protocol FJD-EMILY-23-02 also includes a substudy in the Respiratory Intermediate Care Unit and a substudy in a conventional hospital ward, registered separately.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Interstitial Lung Diseases
  • Pulmonary Hypertension
  • Chronic Respiratory Failure

Keywords

  • closed-loop oxygen therapy
  • automated oxygen titration
  • six-minute walk test
  • ambulatory oxygen
04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 40 to 90 years with a chronic respiratory disease.
  • Indication for exertional oxygen therapy, defined as SpO2 below 88% during a six-minute walk test and/or resting respiratory failure (PaO2 below 60 mmHg).
  • Able to understand the study and sign .

Exclusion criteria

Exclusion Criteria:

  • Decompensated acute or chronic disease with severe organ involvement, such as cardiovascular disease.
  • Musculoskeletal or neurological disease preventing stable and safe walking.
  • Comorbidities or treatments that, by intensity or dose, limit performance of the tests or interpretation of the results (such as alcohol use, beta-blockers, or other neurological or psychiatric drugs).
  • Walking limitation preventing the six-minute walk test, or cardiovascular or connective tissue disease limiting accurate transcutaneous pulse oximetry.
  • Pregnancy or breastfeeding (women of require a negative pregnancy test at screening).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    EMILY.AI first, then fixed flow

    First 6MWT with automatic titration by EMILY.AI; after 30 minutes of rest, second 6MWT with fixed-flow oxygen through the same device.

    Device: EMILY.AI automatic oxygen titration · Other: Fixed-flow oxygen

  • Experimental
    Fixed flow first, then EMILY.AI

    First 6MWT with fixed-flow oxygen through the device; after 30 minutes of rest, second 6MWT with automatic titration by EMILY.AI.

    Device: EMILY.AI automatic oxygen titration · Other: Fixed-flow oxygen

Interventions

  • DeviceEMILY.AI automatic oxygen titration

    Investigational smart oxygen valve with an embedded fuzzy-logic algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate during walking and recovery. Other names: EMILY.AI Smart Valve

  • OtherFixed-flow oxygen

    Standard care: constant oxygen flow set by the physician, delivered through the EMILY.AI device in fixed mode so that the participant cannot distinguish it from automatic titration.

06

What researchers measure

Primary outcomes

  1. Percentage of time with SpO2 within the target range

    Percentage of test time (6 minutes of walking plus 2 minutes of recovery) with SpO2, measured by pulse oximetry, within the predefined target range (88-92%), without delivering oxygen while SpO2 is above the range. Compared between the test with automatic titration by EMILY.AI and the test with fixed flow.

    Time frame: Day 1

Secondary outcomes

  1. Percentage of test time with SpO2 below 88%

    Percentage of test time (walking and recovery) with SpO2 below 88%, compared between conditions.

    Time frame: Day 1

  2. Number of desaturation episodes with SpO2 below 88%

    Number of episodes per test in which SpO2 falls below 88%, compared between conditions.

    Time frame: Day 1

  3. Time to start of oxygen flow correction

    Time in seconds from SpO2 leaving the target range (88-96%) to the start of an oxygen flow change, compared between conditions.

    Time frame: Day 1

  4. Time to return of SpO2 to the target range

    Time in seconds from SpO2 leaving the target range (88-96%) to its return to the range, compared between conditions.

    Time frame: Day 1

  5. Percentage of test time with oxygen delivered while SpO2 is above 92%

    Percentage of test time (walking and recovery) during which oxygen is delivered while SpO2 is above 92%, compared between conditions.

    Time frame: Day 1

  6. Number of episodes with oxygen delivered while SpO2 is above 92%

    Number of episodes per test in which oxygen is delivered while SpO2 is above 92%, compared between conditions.

    Time frame: Day 1

  7. Total oxygen delivered

    Total volume of oxygen delivered (litres) during each test including recovery, compared between conditions.

    Time frame: Day 1

  8. Mean oxygen flow

    Mean oxygen flow (litres per minute) delivered during each test including recovery, compared between conditions.

    Time frame: Day 1

  9. Six-minute walk distance

    Distance walked (metres), compared between conditions.

    Time frame: Day 1

  10. Change in dyspnoea measured with the modified Borg Dyspnoea Scale

    Change from the start to the end of each test in dyspnoea measured with the modified Borg Dyspnoea Scale, which ranges from 0 (no breathlessness at all) to 10 (maximal breathlessness). Higher scores mean a worse outcome. Compared between conditions.

    Time frame: Day 1: before and immediately after each six-minute walk test

  11. Maximum heart rate

    Maximum heart rate (beats per minute) during each test, compared between conditions.

    Time frame: Day 1

  12. Maximum respiratory rate

    Maximum respiratory rate (breaths per minute) during each test, compared between conditions.

    Time frame: Day 1

  13. Perceived difference in exercise capacity between the two tests

    Number of participants answering no, partially or yes to the question "Did you notice differences in your exercise capacity in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

    Time frame: Day 1: within 1 hour after the second six-minute walk test

  14. Perceived difference in breathlessness between the two tests

    Number of participants answering no, partially or yes to the question "Did you notice differences in shortness of breath in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

    Time frame: Day 1: within 1 hour after the second six-minute walk test

  15. Perceived difference in comfort of oxygen delivery between the two tests

    Number of participants answering no, partially or yes to the question "Did you notice differences in the comfort of oxygen delivery in either of the two tests?", and, if so, in which test. Categorical 3-option response, not a scored scale.

    Time frame: Day 1: within 1 hour after the second six-minute walk test

  16. Preference between the two oxygen delivery systems

    Number of participants answering no, partially or yes to the question "Do you prefer either of the two oxygen systems used in the tests?", and, if so, which one. Categorical 3-option response, not a scored scale.

    Time frame: Day 1: within 1 hour after the second six-minute walk test

  17. Preference for continuous automatic flow regulation at home

    Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to regulate the oxygen flow continuously?". Categorical 3-option response, not a scored scale.

    Time frame: Day 1: within 1 hour after the second six-minute walk test

  18. Preference for telemonitored home oxygen

    Number of participants answering no, partially or yes to the question "Would you prefer your home oxygen system to be telemonitored by the medical team?". Categorical 3-option response, not a scored scale.

    Time frame: Day 1: within 1 hour after the second six-minute walk test

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
    Recruiting
    • Sarah Beatrice Heili Frades Zimmermann MD, PhD · ContactSHeili@fjd.es · +34 915 50 48 00
    • Alba Naya Prieto, MD · Contactalba.naya@fjd.es · +34 915 50 48 00
    • Sarah Beatrice Heili Frades Zimmermann, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 87 industry-sponsored interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 8 months is below that.

Counting every sponsor, half of 1,182 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 16, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Dec 20, 2026
CompletionEst.
Dec 20, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938086
Lead sponsor
Aether Tech S.L.
Collaborators
Hospital Universitario Fundación Jiménez Díaz
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Apr 15, 2026
Primary completion
Dec 20, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Nov 16, 2026

Study contacts

Sarah Beatrice Heili Frades, MD, PhD
Contact
SHeili@fjd.es
+34 915 50 48 00
Alba Naya Prieto, MD
Contact
alba.naya@fjd.es
+34 915 50 48 00
Sarah Beatrice Heili Frades, MD, PhD, MD, PhD
principal investigator · Hospital Universitario Fundación Jiménez Díaz

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion